Understanding the biology of urothelial cancer metastasis
- PMID: 29264189
- PMCID: PMC5730871
- DOI: 10.1016/j.ajur.2016.09.005
Understanding the biology of urothelial cancer metastasis
Abstract
Management of unresectable urothelial cancer (UC) has been a clinical challenge for decades. While drug resistance is a key issue, precise understanding of biology of UC metastasis is another challenge for the improvement of treatment outcome of UC patients. Introduction of the cell biology concepts including epithelial-mesenchymal transition (EMT) and cancer stemness seems to explain UC metastasis. Molecular genetics based on gene expression profiling, next generation sequencing, and explosion of non-coding RNA world has opened the door to intrinsic molecular subtyping of UC. Next steps include, based on the recently accumulated understanding, the establishment of novel disease models representing UC metastasis in various experimental platforms, particularly in vivo animal systems. Indeed, novel knowledge molecular genetics has not been fully linked to the modeling of UC metastasis. Further understanding of bladder carcinogenesis is needed particularly with regard to cell of origin related to tumor characteristics including driver gene alterations, pathological differentiations, and metastatic ability. Then we will be able to establish better disease models, which will consequently lead us to further understanding of biology and eventually the development of novel therapeutic strategies for UC metastasis.
Keywords: Animal models; Epithelial-mesenchymal transition; Metastasis; Urothelial carcinoma.
Similar articles
-
High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis.Front Oncol. 2022 Mar 16;12:834249. doi: 10.3389/fonc.2022.834249. eCollection 2022. Front Oncol. 2022. PMID: 35372028 Free PMC article.
-
Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer.Cancer Metastasis Rev. 2015 Dec;34(4):691-701. doi: 10.1007/s10555-015-9589-6. Cancer Metastasis Rev. 2015. PMID: 26328525 Review.
-
Effects of Concurrent Chemoradiotherapy on the Metastasis and the Mesenchymal Transition of Bladder Urothelial Carcinoma Cells.Anticancer Res. 2021 Oct;41(10):4957-4968. doi: 10.21873/anticanres.15309. Anticancer Res. 2021. PMID: 34593443
-
Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.Oncologist. 2021 Aug;26(8):e1395-e1405. doi: 10.1002/onco.13839. Epub 2021 Jun 8. Oncologist. 2021. PMID: 34050578 Free PMC article.
-
Molecular classification of urothelial bladder carcinoma.Mol Biol Rep. 2023 Sep;50(9):7867-7877. doi: 10.1007/s11033-023-08689-7. Epub 2023 Jul 31. Mol Biol Rep. 2023. PMID: 37525073 Free PMC article. Review.
Cited by
-
Comparative oncology: overcoming human cancer through companion animal studies.Exp Mol Med. 2023 Apr;55(4):725-734. doi: 10.1038/s12276-023-00977-3. Epub 2023 Apr 3. Exp Mol Med. 2023. PMID: 37009802 Free PMC article. Review.
-
Hsa-miR-30a-3p overcomes the acquired protective autophagy of bladder cancer in chemotherapy and suppresses tumor growth and muscle invasion.Cell Death Dis. 2022 Apr 21;13(4):390. doi: 10.1038/s41419-022-04791-z. Cell Death Dis. 2022. PMID: 35449123 Free PMC article.
-
Biology and therapy of urological cancer metastasis.Asian J Urol. 2016 Oct;3(4):167-169. doi: 10.1016/j.ajur.2016.09.008. Epub 2016 Sep 23. Asian J Urol. 2016. PMID: 29264185 Free PMC article. No abstract available.
-
Intravesical Therapy for Upper Urinary Tract Urothelial Carcinoma: A Comprehensive Review.Cancers (Basel). 2023 Oct 17;15(20):5020. doi: 10.3390/cancers15205020. Cancers (Basel). 2023. PMID: 37894387 Free PMC article. Review.
-
Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.BMC Cancer. 2023 Jun 20;23(1):565. doi: 10.1186/s12885-023-10930-2. BMC Cancer. 2023. PMID: 37340317 Free PMC article.
References
-
- GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2016/05/29. http://globocan.iarc.fr/Default.aspx
-
- Shinagare A.B., Ramaiya N.H., Jagannathan J.P., Fennessy F.M., Taplin M.E., Van den Abbeele A.D. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196:117–122. - PubMed
-
- von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–4608. - PubMed
-
- Choi W., Czerniak B., Ochoa A., Su X., Siefker-Radtke A., Dinney C. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11:400–410. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources